While Mylan (MYL) has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts (ESRX) , UnitedHealth Group (UNH) and Cigna (CI) will not cover the device.

This article was written by a staff member of TheStreet.

More from Video

Wait, Google Was Almost Called What?

Wait, Google Was Almost Called What?

NYSE Trader: Google-EU Fines Seems Like a One-Off

NYSE Trader: Google-EU Fines Seems Like a One-Off

NYSE Trader: I'm Not Worried About a Flash Crash This Summer

NYSE Trader: I'm Not Worried About a Flash Crash This Summer

NYSE Trader: Why the Rotation Into Financials Stocks Has Legs

NYSE Trader: Why the Rotation Into Financials Stocks Has Legs

Video: NYSE Trader Expects a 'Slow Grind' Back to the January Market Highs

Video: NYSE Trader Expects a 'Slow Grind' Back to the January Market Highs